Phase
Condition
Crohn's Disease
Inflammatory Bowel Disease
Treatment
Biospecimen Collection
Live Freeze-Dried Lactic Acid Bacteria Probiotic
Questionnaire Administration
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Histologically confirmed solid malignancy
Will be starting on ICIs
For cohort 1: Ipilimumab with or without anti-PD-1/PD-L1 including but notlimited to pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, ordurvalumab
For cohort 2: Anti-PD-1/PD-L1 described above with or without chemotherapy
Absolute neutrophil count (ANC) ≥ 1000/mm^3
Platelet count ≥ 75,000/mm^3
Hemoglobin ≥ 9.0 g/dL
Creatinine ≤ 2 x upper limit of normal (ULN)
Serum glutamic-oxaloacetic transaminase (SGOT) [aspartate transaminase (AST)] ≤ 2 xULN
Albumin ≥ 3 g/dL
Willing and able to provide research stool and blood samples
Negative serum pregnancy test done ≤ 7 days prior to enrollment, for women ofchildbearing potential only
Capable of providing valid informed consent
Willing to return to enrolling institution for all study visits (blood draws, etc)
Exclusion
Exclusion Criteria:
Requires prolonged systemic antibiotic therapy for other condition and recentsystemic antibiotic within the past 2 weeks
Fecal microbiota transplant (FMT) within the past 6 months
FMT with an associated serious adverse event related to the FMT product or procedure
Co-morbid systemic illnesses or other severe concurrent disease which, in thejudgment of the investigator, would make the patient inappropriate for entry intothis study or interfere significantly with the proper assessment of safety andtoxicity of over-the-counter probiotics
Immunocompromised patients including patients known to be HIV positive or those onchronic steroids > 20 mg prednisone a day or prednisone-equivalent Note: Must be offsystemic steroids at least 90 days prior to enrollment. However, topical steroids,inhalants or steroid eye drops are permitted
History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn'sdisease, or microscopic colitis
History of chronic diarrhea
History of celiac disease
Currently has a colostomy
Intraabdominal surgery related to gastrointestinal tract within the last 60 days
Evidence of active, severe colitis
History of short gut syndrome or motility disorders
Requires the regular use of medications to manage bowel hypermotility
Active autoimmune disease that has required systemic treatment in the ≤ 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressivedrugs) prior to randomization. Note: Replacement therapy (e.g., thyroxine, insulin,or physiologic corticosteroid replacement therapy for adrenal or pituitaryinsufficiency) is not considered a form of systemic treatment. Patients withvitiligo, Graves' disease, or psoriasis not requiring systemic treatment within thepast 30 days are not excluded
Study Design
Study Description
Connect with a study center
Mayo Clinic in Florida
Jacksonville, Florida 32224-9980
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.